PT-141 for Women: What Bremelanotide Trials Actually Show
Published
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
PT-141, also called bremelanotide, has human trial evidence for a specific sexual-desire disorder. The strongest studies found improvements in desire and related distress, alongside important limitations and adverse effects. Understanding the population, measurements and formulation matters more than a general claim that a peptide “works for women.” RECONNECT phase 3 report
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells research materials. This is commercially interested, AI-assisted educational content, not an independent scientific review. The FDA label, original trial and extension were reviewed in full; the critical reanalysis was reviewed as an abstract. Source access was checked November 14, 2026. Research materials are not established substitutes for approved medicines.

What is approved, and for whom?
Vyleesi is a prescription bremelanotide product. Its October 2026 FDA label covers premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), with distress, after excluding specified medical, relationship and medication-related explanations. It is not indicated for postmenopausal women, men or sexual-performance enhancement. FDA prescribing information
That distinction also separates clinical evidence from research catalog materials. A chemical name on a research vial does not establish equivalence to the approved prescription formulation. Our explanation of research-use-only peptide labels covers why the product's intended use and documentation matter.
Who participated in RECONNECT?
The two randomized, double-blind, placebo-controlled trials lasted 24 weeks and randomized 1,267 women. The efficacy analysis included 1,202 participants; the trial population was predominantly White (85.6%). Palatin Technologies and AMAG Pharmaceuticals funded the trials. Original trial publication
The study 301 registry required HSDD for at least six months. It described generally healthy premenopausal participants and excluded conditions that could explain sexual dysfunction or confound interpretation. Those eligibility rules are part of the evidence: they narrow the question the experiment can answer. Findings from this selected population cannot simply be generalized to every cause of low desire. ClinicalTrials.gov study 301
What changed compared with placebo?
The table separates the two co-primary questionnaire outcomes from the key secondary event outcome. Figures are estimated differences in change between treatment and placebo, in score points. RECONNECT results
Outcome | Study 301 | Study 302 | Interpretation |
|---|---|---|---|
Desire: FSFI desire domain | +0.30 | +0.42 | Higher favors bremelanotide |
Distress: FSDS-DAO item 13 | −0.37 | −0.29 | Lower favors bremelanotide |
Number of satisfying sexual events | No significant difference | No significant difference | The key secondary endpoint was not met |
Both co-primary differences were statistically significant. Trial report
The desire scale runs from 1.2 to 6; the distress item runs from 0 to 4. A change of 0.30 points is therefore not a 30% improvement. Nor does an average describe every participant's experience. The measurement scale, comparison group and individual variation all belong in the interpretation. Registered outcome definitions
For a reusable checklist covering these distinctions, see how to read a peptide study.
What adverse effects were reported?
The current label reports these pooled trial rates. FDA adverse-reaction table
Outcome | Bremelanotide | Placebo |
|---|---|---|
Nausea | 40.0% | 1.3% |
Flushing | 20.3% | 0.3% |
Headache | 11.3% | 1.9% |
Stopping because of adverse reactions | 18% | 2% |
The label also warns about transient blood-pressure increases, reduced heart rate and focal skin darkening. Uncontrolled hypertension and known cardiovascular disease are contraindications. These findings make tolerability and participant selection central to the evidence, rather than incidental footnotes. FDA safety information
What does longer follow-up add?
The 52-week extension enrolled volunteers who had completed the core trials without serious adverse events. Of 856 eligible women, 684 joined and 272 completed the extension. Everyone received bremelanotide; there was no continuing placebo group, and analyses were descriptive. Extension full text
Researchers reported sustained symptom improvements, but this design cannot isolate a long-term treatment effect from expectations, selection or other changes. People who continued may differ from those who declined or stopped. The extension also described a hepatitis case whose connection to bremelanotide was considered unlikely but could not be excluded. Longer observation is useful; it does not demonstrate the absence of rare harm. Extension results and limitations
Why do researchers disagree about the results?
A reanalysis published online in 2023 questioned the validation of several outcome measures and examined previously unpublished registered outcomes. Its authors reported effects ranging from absent to small on those additional measures. This was a critical analysis of the existing program, not a new randomized trial. We reviewed its abstract, not its full text. Spielmans and Ellefson, PubMed abstract
That critique raises a useful reading question: does a headline describe the entire outcome set, or only the measures with favorable findings? A balanced account preserves the positive co-primary results while showing negative endpoints, uncertainty and withdrawals.
Research questions worth answering next
Our editorial priorities would be studies that help readers judge the practical meaning of a result:
How closely do score changes match improvements participants themselves consider worthwhile?
Do findings hold across more diverse populations and clearly defined clinical subgroups?
What happens to participants who discontinue, including their reasons and subsequent outcomes?
Can longer comparative studies better characterize sustained benefit, tolerability and uncommon adverse events?
These are proposed questions for future research. They are not a description of studies conducted or commissioned by Bio Peptides Labs. A useful future protocol would publish its endpoints before enrollment and report the full outcome set, including results that complicate the headline.
Frequently asked questions
Is PT-141 approved for every woman with low desire?
No. The approved indication has a defined population and diagnostic conditions; it is not a general libido claim. FDA indication
Does a statistically significant result guarantee a noticeable benefit?
No. Statistical significance addresses evidence for a group difference. Its practical meaning also depends on the size of the effect, the outcome measured and how participants value the change.
Can a research vial be substituted for the prescription product?
The clinical results do not establish that substitution. Research labeling and a shared compound name do not demonstrate pharmaceutical equivalence.
What should I check when comparing PT-141 articles?
Look for the study population, placebo comparison, outcome definitions, absolute adverse-event rates and withdrawals. Check whether the writer distinguishes a controlled trial from an extension or a reanalysis.
Review method and source access
Sources accessed November 14, 2026. The FDA label, original trial paper and extension were reviewed in full text; the critical reanalysis was available as an abstract. Registry eligibility and outcome definitions were checked through the ClinicalTrials.gov public API. This article reviews evidence and does not provide treatment instructions.
